Acocella G, Bonollo L, Mainardi M, Margaroli P, Tenconi L T
Arzneimittelforschung. 1977;27(6):1221-6.
Two studies were carried out in man with the aim of assessing the serum and urine concentrations of rifampicin administered by i.v. infusion. In patients suffering from various diseases, a dose of 600 mg i.v. proved to be equieffective with a 600 mg oral dose. Repeated administration of a 600 mg dose by i.v. infusion for a week produced serum levels corresponding to those achieved by oral administration. With the i.v. preparation the drop in serum rifampicin levels during continuous administration was less marked than with the oral administration. The recovery of antibiotic in the urine seems to be lower with i.v. than with the oral preparation. The i.v. preparation was very well tolerated by all the patients.
进行了两项人体研究,目的是评估静脉输注利福平后的血清和尿液浓度。在患有各种疾病的患者中,静脉注射600毫克剂量被证明与口服600毫克剂量等效。通过静脉输注重复给予600毫克剂量一周,产生的血清水平与口服给药所达到的水平相当。使用静脉制剂时,持续给药期间血清利福平水平的下降比口服给药时不那么明显。静脉注射制剂在尿液中的抗生素回收率似乎低于口服制剂。所有患者对静脉制剂的耐受性都很好。